Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Novo Nordisk's semaglutide ... currently headed by Novo's own $2 billion-a-year Victoza (liraglutide) brand which stands alongside other drugs such as AstraZeneca's Bydureon (exenatide ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...